Overview

Biomarkers in Women Receiving Chemotherapy and Celecoxib for Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Status:
Terminated

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This phase II clinical trial is studying biomarkers and side effects in women receiving chemotherapy and celecoxib for stage II or stage III breast cancer that can be removed by surgery.

Phase:

Phase 2

Details

Lead Sponsor:

University of Nebraska

Collaborator:

National Cancer Institute (NCI)

Treatments:

Capecitabine
Celecoxib
Cyclophosphamide
Docetaxel
Doxorubicin
Lenograstim
Liposomal doxorubicin